BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yang B, Jie L, Yang T, Chen M, Gao Y, Zhang T, Zhang Y, Wu H, Liao Z. TACE Plus Lenvatinib Versus TACE Plus Sorafenib for Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Prospective Cohort Study. Front Oncol 2021;11:821599. [PMID: 35004336 DOI: 10.3389/fonc.2021.821599] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Ma J, Bo Z, Zhao Z, Yang J, Yang Y, Li H, Yang Y, Wang J, Su Q, Wang J, Chen K, Yu Z, Wang Y, Chen G. Machine Learning to Predict the Response to Lenvatinib Combined with Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma. Cancers 2023;15:625. [DOI: 10.3390/cancers15030625] [Reference Citation Analysis]
2 Deng J, Liao Z, Gao J. Efficacy of Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus: A Systematic Review and Meta-Analysis. Curr Oncol 2023;30:1243-54. [PMID: 36661745 DOI: 10.3390/curroncol30010096] [Reference Citation Analysis]
3 Chen B, Zhang L, Cheng J, Wu T, Lei J, Yang X, Zhang R, Safadi R, Li Y, Si T, Lu Y. Risk Factors for Hepatic Encephalopathy in Hepatocellular Carcinoma After Sorafenib or Lenvatinib Treatment: A Real-World Study. Drug Des Devel Ther 2022;16:4429-37. [PMID: 36597443 DOI: 10.2147/DDDT.S386829] [Reference Citation Analysis]
4 Feng JK, Liu ZH, Fu ZG, Chai ZT, Sun JX, Wang K, Cheng YQ, Zhu HF, Xiang YJ, Zhou LP, Shi J, Guo WX, Zhai J, Cheng SQ. Efficacy and safety of transarterial chemoembolization plus antiangiogenic- targeted therapy and immune checkpoint inhibitors for unresectable hepatocellular carcinoma with portal vein tumor thrombus in the real world. Front Oncol 2022;12:954203. [PMID: 36505818 DOI: 10.3389/fonc.2022.954203] [Reference Citation Analysis]
5 Wang H, Zhang G, Yang X, Lu Z, Zhao H. Lenvatinib plus immune checkpoint inhibitors or locoregional therapy in unresectable hepatocellular carcinoma: Lessons learned and moving forwards. Biochim Biophys Acta Rev Cancer 2022;1878:188841. [PMID: 36423747 DOI: 10.1016/j.bbcan.2022.188841] [Reference Citation Analysis]
6 Xie Q, Huang L, Gao F, Liu D, Wang X, Jiang K, Gong J, Zhao X, Gao B, Lei Z. Efficacy of lenvatinib combined with sequential transarterial chemoembolization for primary hepatocellular carcinoma and the effects on serum basic fibroblast growth factor and vascular endothelial growth factor. Front Pharmacol 2022;13:965770. [DOI: 10.3389/fphar.2022.965770] [Reference Citation Analysis]
7 Liu Y, Qiao Y, Zhou M, Guo J, Lin Y, Li W, An C, Li C. Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and sequential ablation in the treatment of advanced hepatocellular carcinoma. Cancer Med 2022. [PMID: 36254376 DOI: 10.1002/cam4.5366] [Reference Citation Analysis]
8 Yuan P, Song J, Wang F, Zhu G, Chen B. Combination of TACE and Lenvatinib as a promising option for downstaging to surgery of initially unresectable intrahepatic cholangiocarcinoma. Invest New Drugs 2022;40:1125-32. [PMID: 35793038 DOI: 10.1007/s10637-022-01257-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Sun L, Xu X, Meng F, Liu Q, Wang H, Li X, Li G, Chen F. Lenvatinib plus transarterial chemoembolization with or without immune checkpoint inhibitors for unresectable hepatocellular carcinoma: A review. Front Oncol 2022;12:980214. [DOI: 10.3389/fonc.2022.980214] [Reference Citation Analysis]
10 Qu W, Ding Z, Qu X, Tang Z, Zhu G, Fu X, Zhang Z, Zhang X, Huang A, Tang M, Tian M, Jiang X, Huang R, Tao C, Fang Y, Gao J, Wu X, Zhou J, Fan J, Liu W, Shi Y. Conversion therapy for initially unresectable hepatocellular carcinoma using a combination of toripalimab, lenvatinib plus TACE: real-world study. BJS Open 2022;6. [DOI: 10.1093/bjsopen/zrac114] [Reference Citation Analysis]
11 Zhang JX, Chen YX, Zhou CG, Liu J, Liu S, Shi HB, Zu QQ. Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: A comparative retrospective study. Hepatol Res 2022;52:794-803. [PMID: 35698267 DOI: 10.1111/hepr.13801] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Bai S, Hu L, Liu J, Sun M, Sun Y, Xue F. Prognostic Nomograms Combined Adjuvant Lenvatinib for Hepatitis B Virus–related Hepatocellular Carcinoma With Microvascular Invasion After Radical Resection. Front Oncol 2022;12:919824. [DOI: 10.3389/fonc.2022.919824] [Reference Citation Analysis]